Literature DB >> 6414689

High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.

R Stuart-Harris, P G Harper, S B Kaye, E Wiltshaw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6414689     DOI： 10.1016/s0305-7372(83)80023-1

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

1.  Basic principles in preclinical cancer chemotherapy.

Authors:  N Brock; J Pohl; B Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 2.  The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.

Authors:  Xin Xiao; Wei Wang; Zhen Wang
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

3.  Ifosfamide in pediatric malignant solid tumors.

Authors:  C B Pratt; E C Douglass; E L Etcubanas; M P Goren; A A Green; F A Hayes; M E Horowitz; W H Meyer; E I Thompson; J A Wilimas
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.

Authors:  C A James; T G Mant; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

5.  Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.

Authors:  T A Wiklund; C P Blomqvist; M Virolainen; I Elomaa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.

Authors:  R E Coleman; P G Harper; C Gallagher; R Osborne; E M Rankin; A C Silverstone; M L Slevin; R L Souhami; J S Tobias; C W Trask
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.

Authors:  N S Tchekmedyian; M J Egorin; B E Cohen; R S Kaplan; E Poplin; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.